Specjalistyczny Gabinet Diabetologiczny Radosław Rumianowski

Research site

Poland ul. Szarych Szeregów 38, Gorzów Wielkopolski, Poland

1 trial recruiting
Arteriosclerosis · Obesity · Overweight
Adult patients

About Specializations

Specjalistyczny Gabinet Diabetologiczny Radosław Rumianowski in Gorzów Wielkopolski, Poland specialises in clinical trials of conditions such as Arteriosclerosis, Obesity, Overweight, Type 2 diabetes mellitus, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

The clinic is advancing research on atherosclerotic cardiovascular disease, aiming to test new medicines that could lower the risk of heart attacks and strokes in patients with overweight or obesity.

Evaluation of zenagamtide added to standard care for reducing major adverse cardiovascular events
Investigation of cardiovascular outcomes in individuals with obesity
Study of time to first MACE as a primary endpoint

Specjalistyczny Gabinet Diabetologiczny Radosław Rumianowski collaborates with investigators to bring innovative cardiovascular therapies to patients in Gorzów Wielkopolski.

Nutritional and Metabolic Diseases

Research at the site concentrates on type 2 diabetes and related metabolic disorders, evaluating novel agents that may improve blood sugar control and promote weight loss.

Comparison of CagriSema versus semaglutide on HbA1c reduction
Assessment of body‑weight changes in participants with obesity
Exploration of combined metformin and SGLT2‑inhibitor regimens

The Gorzów Wielkopolski center provides patients with access to cutting‑edge metabolic research while maintaining a patient‑focused approach.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

ul. Szarych Szeregów 38Gorzów WielkopolskiPoland

Open in maps ↗

Recruiting now: 1 trial
Conditions studied: 4

More sites in Gorzów Wielkopolski Poland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

2 clinical trials

Obesity+2

Recruiting

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Effect of zenagamtide on major adverse cardiovascular events in overweight or obese adults with established atherosclerotic cardiovascular disease

Investigational

Poland

Participants:18–64 years
Substances:POLYPEPTIDE CONSISTING OF A GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST AND AN AMYLIN RECEPTOR AGONIST, CONNECTED BY A LINKER WITH 4 GLYCINE RESIDUES, AND CONNECTED TO A C18 FATTY ACID SIDE CHAIN
Sponsor:Novo Nordisk A/S

Contact Research Centre

Type 2 diabetes mellitus

Not recruiting

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug

A study comparing cagrilintide and semaglutide combination to semaglutide, cagrilintide, and placebo in adults with type 2 diabetes on metformin

Registered drug

Poland

Participants:18–64 years · 65+ years
Substances:Cagrilintide
Sponsor:Novo Nordisk A/S

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites